Conversely, FOXP3+ regulatory T cells assessed in treatment naïve tumors were shown to be an indicator of poor prognosis in HR+ breast cancer, but of favorable prognosis in HR-/HER2+ tumors (38). The gene discussed is ERBB2; the disease is breast carcinoma.